SEC Form 4 · accession 0001649904-26-000023
RHYTHM PHARMACEUTICALS, INC. · RYTM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Hunter C Smith
Officer — Chief Financial Officer
Period of report
Aug 31, 2026
Accepted (ET)
Sep 1, 2026 · 4:22 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001649904
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 31, 2026 | M | 57,187 | $25.79 | A | 176,798 | D | |
| Common StockF2 | Aug 31, 2026 | S | 23,072 | $104.5871 | D | 153,726 | D | |
| Common StockF3 | Aug 31, 2026 | S | 11,514 | $105.3702 | D | 142,212 | D | |
| Common StockF4 | Aug 31, 2026 | S | 28,188 | $106.2029 | D | 114,024 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F5 | $25.79 | Aug 31, 2026 | M | 57,187 | D | — | Feb 13, 2028 | Common Stock | 57,187 | 3,813 | D |
Explanation of responses
- F1The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026.
- F2The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $104.04 to $105.03 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $105.04 to $106.01 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $106.05 to $106.88 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5This option was granted on February 14, 2018 and the shares underlying this option vested in sixteen equal quarterly installments.